<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="288">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323592</url>
  </required_header>
  <id_info>
    <org_study_id>MP-19 023_2020</org_study_id>
    <nct_id>NCT04323592</nct_id>
  </id_info>
  <brief_title>Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome</brief_title>
  <acronym>MP-C19</acronym>
  <official_title>Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Trieste</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Trieste</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution
      to the lack of ICU beds and increasing deaths day after day.

      A recent retrospective Chinese paper (JAMA Intern Med, online March 13, 2020) showed
      impressive positive effect of methylprednisolone (MP) on survival of SARS-CoV-2 critically
      ill patients. We're routinely using MP for severe pneumonia-ARDS with acute respiratory
      failure with very good results.

      The main objective of this multi-centre observational trial is to evaluate the efficacy of
      low dose prolonged infusion of methylprednisolone (MP) for patients with severe acute
      respiratory syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of two groups of patients SARS-CoV-2 positive with severe acute respiratory
      syndrome:

        1. Consecutively treated with low prolonged doses of methylprednisolone

        2. Historical patients never treated with corticosteroids

      The two group will be matched (1:1) according to the following criteria:

        1. sex

        2. age &lt;10 years difference

        3. CRP level at admission (difference &lt;20%)

        4. SOFA score (difference &lt;20%)

        5. P/F difference &lt;20%

      Anti-viral agents, chloroquine, respiratory support (any), and antibiotics (any) will be
      permitted to each study group.

      Corticosteroids use, other than methylprednisolone for MP-treated group is a reason of
      drop-out.

        1. Methylprednisolone treated-group will receive at study entry Methylprednisolone 80mg iv
           bolus followed by Methylprednisolone 80mg in 240cc 0.9% saline iv infusion at 10cc/h for
           at least 8 days or more until PCR&lt;20mg/L and/or P/F&gt;350. Then methylprednisolone 16mg
           BID os slowly tapering until PCR normal range +/- normal range and P/F&gt;400.

           Group 1 will be treated also with usual respiratory support (oxygen, O2 high-flow nasal
           cannula, CPAP, noninvasive ventilation, invasive mechanical ventilation, ECMO).

        2. Control group will be selected and matched among historical patients with the same
           disease and treatment, but without any administration of methylprednisolone and other
           corticosteroids.

      Matching criteria will be the following (all of them):

        1. same sex

        2. age +/- 10 years

        3. C-reactive protein within 20% value difference

        4. P/F within 20% value difference

        5. SOFA score within 20% value difference
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 23, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>52 consecutively recruited patients will be treated with methylprednisolone according to the study protocol. Each patient will be compared with &quot;historical&quot; but concurrent patients never treated with corticosteroids and strictly matched according to predefined criteria.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite primary end-point</measure>
    <time_frame>28 days</time_frame>
    <description>Death or ICU admission or Invasive mechanical ventilation (yes/not, at least one of three of the composite end-point)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>28 days</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Admission to ICU</measure>
    <time_frame>28 days</time_frame>
    <description>yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endotracheal intubation (invasive mechanical ventilation)</measure>
    <time_frame>28 days</time_frame>
    <description>yes/no</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of C-reactive protein or CRP</measure>
    <time_frame>14 days and 28 days</time_frame>
    <description>mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>number of days free from mechanical ventilation (invasive or not)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
  <condition>Coronavirus Infections</condition>
  <condition>ARDS, Human</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone treated consecutive cases</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at low prolonged dose.
At admission, inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls (non-methylprednisolone treated subjects)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Concurrent patients, also &quot;historical&quot;, with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone given at low prolonged dose infusion after initial 80mg iv bolus at admission followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description</description>
    <arm_group_label>Methylprednisolone treated consecutive cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>usual standard of care:
oxygen therapy (regular or high-flow) and monitoring
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
ECMO when needed and available
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
    <arm_group_label>Controls (non-methylprednisolone treated subjects)</arm_group_label>
    <arm_group_label>Methylprednisolone treated consecutive cases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. SARS-CoV-2 positive

          2. Age &gt;17 years and &lt; 80 years

          3. P/F &lt; 250 mmHg

          4. Bilateral pneumonia (infiltrates/interstitial)

          5. CRP &gt;10mg/dL (or &gt;100mg/L)

          6. Alternatively to 4-5-6 criteria a diagnosis of ARDS according to the Berlin definition
             (JAMA 2012)

        Exclusion Criteria:

          -  Heart failure as predominant cause of acute respiratory failure

          -  Decompensated liver cirrhosis

          -  Cancer

          -  Organ transplantation

          -  HIV+

          -  dialysis

          -  long-term oxygen therapy

          -  Idiopathic pulmonary fibrosis

          -  Progressive neurmomuscular disorders (e.g. Duchenne, Pompe, ALS)

          -  immunosupressive treatments

          -  Chronic use of corticosteroids

          -  Use of tocilizumab

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Salton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Trieste</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Salton, MD</last_name>
    <phone>3486986287</phone>
    <phone_ext>4667</phone_ext>
    <email>francesco.salton@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marco Confalonieri, MD</last_name>
    <phone>3356895168</phone>
    <email>mconfalonieri@units.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marco Confalonieri</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>marco confalonieri, MD</last_name>
      <phone>+393356895168</phone>
      <email>mconfalonieri@units.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesco confalonieri, MD</last_name>
      <phone>3486986287</phone>
      <email>francesco.salton@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Trieste</investigator_affiliation>
    <investigator_full_name>marco confalonieri</investigator_full_name>
    <investigator_title>Head of Pulmonology and Critical care Dept.</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2,</keyword>
  <keyword>SARS</keyword>
  <keyword>ARDS</keyword>
  <keyword>Methylprednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Anonymised data will be available only to data manager who can visualise clinical chart anytime when is needed</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

